Clinical TrialMay 19, 2026, 07:16 AM
BioLineRx GLIX1 Shows Potent Anti-Tumor Effect in GBM Preclinical Studies
AI Summary
BioLineRx and Hemispherian announced highly encouraging new preclinical data for GLIX1, demonstrating potent anti-tumor effects in Glioblastoma (GBM). The data showed robust anti-tumor activity in orthotopic CDX GBM models and, notably, a strong effect in a Temozolomide (TMZ)-resistant patient-derived xenograft (PDX) GBM model where TMZ had no impact. These compelling results further support the recently initiated Phase 1/2a clinical trial evaluating GLIX1 for recurrent and progressive GBM and other high-grade gliomas, highlighting its potential to address a high unmet medical need.
Key Highlights
- GLIX1 demonstrated robust anti-tumor activity in orthotopic cell-derived xenograft (CDX) GBM models.
- Significant tumor growth inhibition and survival benefit were observed across all GLIX1 doses tested.
- GLIX1 showed a robust anti-tumor effect in a subcutaneous TMZ-resistant patient-derived xenograft (PDX) GBM model.
- Temozolomide (TMZ) showed no effect in the TMZ-resistant PDX model.
- New preclinical data further supports the recently initiated Phase 1/2a clinical trial for GLIX1 in GBM.
- Phase 1/2a trial updates are anticipated during H2 2026, with full dose escalation results expected in 2027.
- GLIX1 is a first-in-class, orally administered, brain penetrating small molecule activator of the TET2 pathway.
Price Impact
More from BLRX